By efain on
Phone
021-58356573
Email
info@immuneonco.com
ClinicalTrials.gov URL
https://clinicaltrials.gov/ct2/results?cond=&term=&type=&rslt=&age_v=&gndr=&intr=&titles=&outc=&spons=immuneonco&lead=&id=&cntry=&state=&city=&dist=&locn=&rsub=&strd_s=&strd_e=&prcd_s=&prcd_e=&sfpd_s=&sfpd_e=&rfpd_s=&rfpd_e=&lupd_s=&lupd_e=&sort=
Acknowledgement
7 business days
EA Page
http://www.immuneonco.com/
Sponsor
ImmuneOnco Biopharmaceuticals Inc.
EA Therapies for Single Patient

IMM2902

IMM2902 is a recombinant bispecific monoclonal antibody. The indication is the use of IMM2902 in patients with HER2-expressing advanced solid tumors, breast cancer and gastric cancer.

EA Policies for Single Patient

Immuneonco will consider providing a requesting physician with pre-approval access to a specific investigational drug, for the treatment of an individual patient outside of a clinical trial, when certain conditions are met. These conditions include the following:

  • The patient has a serious or life-threatening illness or condition and is either no longer responsive to or no longer able to tolerate any available treatment option.
  • The investigational drug is in active clinical development with sufficient data available to determine an appropriate dose and schedule for the patient’s specific condition.
  • A benefit-risk analysis, based on both the available clinical data as well as the requesting physician’s assessment of the individual patient’s condition and history, supports making the investigational drug available.
  • Making the investigational drug available will not negatively impact or delay the conduct of clinical trials or regulatory review or approval of the investigational drug for broader patient access.
  • Adequate supply of the investigational drug is available.

Immuneonco is committed to evaluating all requests in a fair and equitable manner. All requests must be submitted by the patient’s treating physician. Immuneonco may require more detailed information in order to fully evaluate a request. Each request will be given careful consideration by Immuneonco whose decisions are final.

Physicians seeking pre-approval access for patients with no alternative treatment options should submit their requests to the mailbox (info@immuneonco.com). We regularly monitor this mailbox and will use our best efforts to acknowledge each submitted request within 7 working days after receipt.

To learn more about the EA policy by Immuneonco, please visit www.immuneonco.com.

EA Policies for Disease / Category

http://immuneonco.com/info.php?class_id=103102